Ambrx Biopharma PE Ratio 2020-2022 | AMAM

Current and historical p/e ratio for Ambrx Biopharma (AMAM) from 2020 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Ambrx Biopharma PE ratio as of November 25, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Ambrx Biopharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-11-25 0.49 inf
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.019B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.477B 10.28
GSK (GSK) United Kingdom $69.125B 8.67
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
QIAGEN (QGEN) Netherlands $11.120B 18.98
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.592B 0.00
Arcus Biosciences (RCUS) United States $1.934B 29.03
Biohaven (BHVN) United States $1.080B 0.00
Emergent Biosolutions (EBS) United States $0.594B 4.67
Zymeworks (ZYME) Canada $0.494B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.276B 0.00
Enzo Biochem (ENZ) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00